F-1/A: Shenni Holdings Files for $18 Million IPO to List on NASDAQ

Shenni Holdings Limited, a Cayman Islands-based medical device company, has filed an amended F-1 registration statement for its initial public offering, seeking to raise up to $18 million.

Summary

• Shenni Holdings Limited, a Cayman Islands holding company with operations in China, has filed an amended registration statement for an initial public offering (IPO).
• The company plans to offer 3,000,000 ordinary shares with an expected price range of $4 to $6 per share.
• Shenni Holdings intends to list its ordinary shares on the NASDAQ Capital Market under the symbol SNI.
• The company's business is conducted through its subsidiaries in China, focusing on the manufacture and distribution of urology medical devices and care products, as well as the distribution of cardiovascular and cerebrovascular medical devices.
• D. Boral Capital is acting as the underwriter for the offering.
• Mr. Minghai Zhou, the Chairman of the board, will beneficially own 54.5% of the voting power upon completion of the offering, making Shenni Holdings a controlled company.
• The company's revenue for the fiscal year ended March 31, 2024, was approximately $10.58 million, a significant increase from $0.62 million in the previous fiscal year.
• Net income for the same period was approximately $1.54 million, compared to a net loss of $0.12 million in the fiscal year ended March 31, 2023.
• For the six months ended September 30, 2024, revenue was approximately $11.18 million and net income was approximately $1.87 million.
• The company plans to use the net proceeds from the IPO for new product development, expansion of production facilities, marketing and promotion, and working capital.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to the company's strong revenue and profit growth. However, risks associated with operating in China and being a controlled company temper the overall sentiment.

Positives

• The company experienced substantial revenue growth in fiscal year 2024, reaching $10.58 million.
• Shenni Holdings achieved a net income of $1.54 million in fiscal year 2024, a significant turnaround from the previous year's net loss.
• The company has a clear plan for utilizing the IPO proceeds to drive future growth.
• The company's revenue increased significantly to $11.18 million in the six months ended September 30, 2024, with a net income of $1.87 million.

Negatives

• The company will be a controlled company, which may reduce corporate governance protections for minority shareholders.
• The company operates in a highly regulated industry and is subject to various risks associated with doing business in China.
• The company relies on a limited number of vendors, and the loss of one of our significant vendors could harm our business, and the loss of any one of such vendors could have a material adverse effect on our business.
• The company has a substantial customer concentration, with a limited number of customers accounting for a large portion of our revenues.

Risks

• Changes in China's economic, political, or social conditions could adversely affect the company's business.
• The company may face difficulties in enforcing judgments against its officers and directors, as they reside outside the United States.
• The Holding Foreign Companies Accountable Act (HFCA Act) could lead to delisting of the company's shares if the PCAOB cannot inspect the company's auditor.
• The company is subject to cybersecurity risks and data privacy regulations in China.
• The company is subject to the relevant filing procedures of the CSRC in connection with our overseas offerings under the New Overseas Listing Rules, and we cannot assure you that we will be able to timely make such filing, in which case we may face sanctions by the CSRC or other PRC regulatory agencies for failure to timely file with the CSRC for such offerings.

Future Outlook

The company aims to bring smarter, efficient, and accessible and minimally invasive surgical instruments to doctors and patients in China and plans to develop a total of 20 new product in the next 2-3 years.

Management Comments

• We aim to bring smarter, efficient, and accessible and minimally invasive surgical instruments to doctors and patients in China.

Industry Context

The medical device industry in China is experiencing growth due to factors such as an aging population, changing lifestyles, and increasing healthcare awareness. The company operates in the urology and cardiovascular/cerebrovascular segments, which are both areas of increasing medical need.

Comparison to Industry Standards

• Jiangxi Langhe Medical Devices Co., Ltd. is a main competitor in urology medical devices.
• Weihai Medison Medical Devices Co., Ltd. is a main competitor in urology medical devices.
• Shanghai MicroPort Medical Devices Co., Ltd. is a main competitor in cardiovascular and cerebrovascular medical devices.
• Shenzhen Huitai Medical Devices Co., Ltd. is a main competitor in cardiovascular and cerebrovascular medical devices.
• ShineLong International Health Development (Liaoning) Co., Ltd., Handan Kailin Sanitary Products Co., Ltd., Guangzhou NuSiman Biotechnology Co., Ltd., Jiangxi Wulinxiang Biotechnology Co., Ltd., Shaanxi ShiJiu Biotechnology Co., Ltd., Hebei JiaAiJian Pharmaceutical Technology Co., Ltd., Weifang Hongyang Pharmaceutical Co., Ltd., Jiangxi Anko Yan Biotechnology Co., Ltd., Shenzhen Renchu Medical Supplies Co., Ltd., Dongguan Gusentang Pharmaceutical Co., Ltd. are main competitors in urology care products.

Related Party Transactions

• The company has engaged in loan transactions with related parties, including Jiangxi Yuansheng Langhe Pharmaceutical Co., Ltd., Minghai Zhou, and Xiaoping Zhou.
• The company leases property from Jiangxi Yuansheng Langhe Pharmaceutical Co., Ltd.

Stakeholder Impact

• Shareholders may benefit from the company's growth and potential increase in share value.
• Employees may benefit from the company's expansion and increased job opportunities.
• Customers may benefit from the company's development of new and improved medical devices.
• Suppliers may benefit from increased orders and business opportunities with the company.

Next Steps

• The company will seek approval to list its ordinary shares on the NASDAQ Capital Market.
• The company will complete the offering and receive the net proceeds.
• The company will implement its growth strategies, including investing in R&D, expanding its market presence, and building its brand.

Key Dates

Keywords

IPO, Shenni Holdings, medical devices, urology, cardiovascular, cerebrovascular, China, NASDAQ, offering, CSRC, HFCA Act